C-reactive protein predicts tumor necrosis factor-α blocker retention rate in axial ankylosing spondylitis

Journal of Rheumatology

Volumn 34, Issue 10, 2007, Pages 2078-2081

  Luc, Mathieu ^a   Gossec, Laure ^a   Ruyssen Witrand, Adeline ^a   Salliot, Carine ^a   Duclos, Muriel ^a   Guignard, Sandra ^a   Dougados, Maxime ^a  

^a Cochin Hospital ^*  (France)

Author keywords

Axial ankylosing spondylitis; C reactive protein; Retention rate; Tumor necrosis factor blocker

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; C-REACTIVE PROTEIN; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35148883476     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61 Suppl 3:40-50.
2. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
3. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind; placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
4. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678-81.
5. Braun J, Pham T, Sieper J, et al. ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
7. Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004;63:ii32-9.
8. Pincus T, Stein CM. Why randomised controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15:S27-S38.
9. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
10. Stone MA, Payne U, Pacheco-Tena C, Inman RD. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004;63:84-7.
11. Davis JC, van der Heijde DM, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32:1751-4.
12. Burgos-Vargas R, Rojas-Serrano J. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis. J Rheumatol 2005;32:1637-40.